Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

1. An ophthalmic pharmaceutical composition comprising as active ingredient a combination of:

a) glycine and proline; and

b) sodium hyaluronate

wherein glycine, L-proline and sodium hyaluronate are comprised within the following percentage ranges by weight:

glycine: 0.01 to 0.5%;

L-proline: 0.06 to 0.09%; and

sodium hyaluronate: 0.1 to 0.5%.

2. The ophthalmic pharmaceutical composition of claim 1 , the composition further comprising as active ingredient:

c) lysine hydrochloride and leucine.

3. The ophthalmic pharmaceutical composition of claim 2 , wherein lysine hydrochloride is L-lysine hydrochloride, leucine is L-leucine and wherein L-lysine hydrochloride and L-leucine are comprised within the following percentage ranges by weight:

L-lysine hydrochloride: 0.01 to 0.02%; and

L-leucine: 0.005 to 0.02%.

4. The ophthalmic pharmaceutical composition of claim 1 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate have the following percentage ranges by weight:

glycine: 0.1%

L-proline: 0.075%; and

sodium hyaluronate: 0.3%.

5. The ophthalmic pharmaceutical composition of claim 2 , wherein lysine hydrochloride is L-lysine hydrochloride, leucine is L-leucine and wherein L-lysine hydrochloride and L-leucine have the following percentage ranges by weight:

L-lysine hydrochloride: 0.014%; and

L-leucine: 0.011%.

6. The ophthalmic pharmaceutical composition of claim 1 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel.

7. The ophthalmic pharmaceutical composition of claim 2 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel.

8. The ophthalmic pharmaceutical composition of claim 3 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel.

9. The ophthalmic pharmaceutical composition of claim 4 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel.

10. The ophthalmic pharmaceutical composition of claim 5 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel.

11. A method to treat a corneal ulceration in a patient, the method comprising

administering to the patient the ophthalmic pharmaceutical composition of claim 1 ,

to treat the corneal ulceration in the patient.

12. A method to treat a corneal ulceration in a patient, the method comprising

administering to the patient the ophthalmic pharmaceutical composition of claim 2 , to treat the corneal ulceration in the patient.

13. A method to treat a lesion of pathological, traumatic, surgical, or parasurgical origin in a patient, the method comprising

administering to the patient the ophthalmic pharmaceutical composition of claim 1 , to treat the lesion of pathological, traumatic, surgical, or parasurgical origin in the patient.

14. A method to treat a lesion of pathological, traumatic, surgical, or parasurgical origin in a patient, the method comprising

administering to the patient the ophthalmic pharmaceutical composition of claim 2 , to treat the lesion of pathological, traumatic, surgical, or parasurgical origin in the patient.

15. A method to treat symptoms of dry eye in a patient, the method comprising

administering to the patient the ophthalmic pharmaceutical composition of claim 1 , to treat the symptoms of dry eye in the patient.

16. A method to treat symptoms of dry eye in a patient, the method comprising

administering to the patient the ophthalmic pharmaceutical composition of claim 2 , to treat the symptoms of dry eye in the patient.